IT services firm Coforge saw its shares tumble more than 5% after Chairman Om Prakash Bhatt resigned amid concerns raised by an internal audit over the company's board evaluation process.
Indian equity benchmarks opened lower on September 9 as Brent crude traded near $100 a barrel following the widening of the US-Iran conflict and Houthi attacks on Saudi energy infrastructure, with IT stocks leading the sell-off.
India's primary market scripted history on September 9 as ten initial public offerings opened for subscription simultaneously, seeking to raise nearly Rs 6,950 crore in one of the busiest single days for IPO activity in nearly three decades.
Subscription-based cooling platform Circolife has raised $4.5 million in a pre-Series A round anchored by entrepreneur Bharat Jaisinghani, aiming to scale its AI-augmented IoT-enabled air-conditioning subscriptions from 10,000 to 40,000 units within two years.
Lightsage, formerly known as API-Rex, has raised $4 million in seed funding led by Nexus Venture Partners to build infrastructure that makes software products discoverable and purchasable by autonomous AI agents.
French AI startup Mistral AI has raised EUR 3 billion in a Series D round led by Samsung at a EUR 21 billion valuation, ranking among the largest private technology funding rounds ever completed in Europe.
Stoke Space has completed the initial $1 billion close of a Series E round to develop a fully reusable orbital rocket, taking its total capital raised to roughly $2.3 billion as it prepares for its first Nova launch.
Indian equity benchmarks opened sharply lower on September 9, with the Sensex shedding 490 points and Nifty slipping below 23,550, as foreign institutional selling and a large RBI liquidity withdrawal weighed on sentiment.
Brent crude climbed past $94 a barrel, near three-month highs, after fresh attacks on Saudi Aramco facilities and Iran-backed Houthi militants claimed responsibility for targeting a major refinery, deepening concerns over global oil supply.
Seattle Children's Hospital spinout BrainChild Bio has raised $116 million in Series A funding to advance a CAR-T cell therapy for children with diffuse intrinsic pontine glioma, one of pediatric oncology's hardest targets.